410 related articles for article (PubMed ID: 19846971)
1. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
Powell S; Dudek AZ
Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
[TBL] [Abstract][Full Text] [Related]
2. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
Pappo I; Lotem M; Klein M; Orda R
Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
[TBL] [Abstract][Full Text] [Related]
3. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
[TBL] [Abstract][Full Text] [Related]
4. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Kammula US; White DE; Rosenberg SA
Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
[TBL] [Abstract][Full Text] [Related]
5. High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy.
Buzaid AC; Schmerling RA; Vieira Guedes RA; de Freitas D; William WN
Melanoma Res; 2011 Aug; 21(4):370-5. PubMed ID: 21558968
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B
Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
8. Stage-IV melanoma and pulmonary metastases: factors predictive of survival.
Neuman HB; Patel A; Hanlon C; Wolchok JD; Houghton AN; Coit DG
Ann Surg Oncol; 2007 Oct; 14(10):2847-53. PubMed ID: 17680317
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
10. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
Atkins MB; Kunkel L; Sznol M; Rosenberg SA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S11-4. PubMed ID: 10685652
[TBL] [Abstract][Full Text] [Related]
11. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
Tarhini AA; Millward M; Mainwaring P; Kefford R; Logan T; Pavlick A; Kathman SJ; Laubscher KH; Dar MM; Kirkwood JM
Cancer; 2009 Feb; 115(4):859-68. PubMed ID: 19140204
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H
Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
14. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
Boyd KU; Wehrli BM; Temple CL
J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
[TBL] [Abstract][Full Text] [Related]
15. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
Royal RE; Steinberg SM; Krouse RS; Heywood G; White DE; Hwu P; Marincola FM; Parkinson DR; Schwartzentruber DJ; Topalian SL; Yang JC; Rosenberg SA
Cancer J Sci Am; 1996; 2(2):91-8. PubMed ID: 9166506
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
17. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
[TBL] [Abstract][Full Text] [Related]
18. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of metastatic malignant melanoma with interleukin-2].
Dorval T; Fridman WH; Mathiot C; Sastre X; Pouillart P
Bull Cancer; 1992; 79(8):781-7. PubMed ID: 1467601
[TBL] [Abstract][Full Text] [Related]
20. [High-dose Roncoleukin in patients with disseminated cutaneous melanoma: a phase 1 study].
Moiseenko VM; Novik AV; Orlova RV; Protsenko SA; Mikhaĭlichenko TD; Semenova AI; Tiukavina NV
Vopr Onkol; 2005; 51(5):546-9. PubMed ID: 16756008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
